Clinical trial
A Phase 1b, Prospective, Randomized, Single-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety of FX-345 Administered as a Single Intratympanic Injection in Adults With Acquired Adult-Onset Sensorineural Hearing Loss
NCT05664100 is registered in ClinicalTrials.gov with Frequency Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Prospective, Randomized, Single-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety of FX-345 Administered as a Single Intratympanic Injection in Adults With Acquired Adult-Onset Sensorineural Hearing Loss
- Lead sponsor
- Frequency Therapeutics
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- December 15, 2022
- Completion date
- April 12, 2023
- Enrollment
- 6 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.